BPHL
Valacyclovir hydrolase
Protein Summary
Serine hydrolase that catalyzes the hydrolytic activation of amino acid ester prodrugs of nucleoside analogs such as valacyclovir and valganciclovir. Activates valacyclovir to acyclovir. May play a role in detoxification processes. It is a specific alpha-amino acid ester hydrolase that prefers small, hydrophobic, and aromatic side chains and does not have a stringent requirement for the leaving group other than preferring a primary alcohol. This gene encodes a member of the serine protease family of hydrolytic enzymes which contain a serine in their active site. The encoded protein may play a role in activation of the antiviral prodrug valacyclovir. Alternatively spliced transcript variants have been described.[provided by RefSeq, Jan 2009]
- ENST00000380375
- ENSP00000369734
- ENSG00000137274
- ENST00000380379
- ENSP00000369739
- ENST00000434640
- ENSP00000390472
- MCNAA
- MCNAA
- BPH-RP
- VACVASE
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
histone modification site profile | 0.92 | ||
disease perturbation | 0.9 | ||
co-expressed gene | 0.89 | ||
virus perturbation | 0.76 | ||
cell type or tissue | 0.73 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 34.79 (req: < 5)
Gene RIFs: 4 (req: <= 3)
Antibodies: 122 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 34.79 (req: >= 5)
Gene RIFs: 4 (req: > 3)
Antibodies: 122 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 4
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0